Metreleptin
Mechanism :
It is a recombinant human leptin analog that binds to and activates the human leptin receptor to treat complications of leptin deficiency associated with generalized lipodystrophy.
Indication :
- Lipodystrophy: Replacement therapy to treat the complications of leptin deficiency, in addition to diet, in patients with congenital or acquired generalized lipodystrophy.
- Limitations of use: Not indicated for use in patients with HIV-related lipodystrophy or for use in patients with metabolic disease without concurrent evidence of congenital or acquired generalized lipodystrophy.
Contraindications :
Hypersensitivity to metreleptin or any component of the formulation; general obesity.
Dosing :
≤40 kg:
Initial dose: 0.06 mg/kg SC once daily; increase or decrease by 0.02 mg/kg daily. Maximum dose: 0.13 mg/kg once daily.
>40 kg:
Initial dose: 2.5 mg (Males) or 5 mg (females) SC once daily; increase or decrease by 1.25-2.5 mg daily. Maximum dose: 10 mg once daily.
Adverse Effect :
Headache, dizziness, urticarial, hypoglycaemia, weight loss, ovarian cyst, decreased glucose tolerance, diabetes mellitus, hypertriglyceridemia, proteinuria, nausea, vomiting, anemia, immunogenicity, sever infection, erythema at injection site, arthralgia, fever.
Interaction :
Estrogen Derivatives & Progestins: Metreleptin may decrease the serum concentration of Estrogen Derivatives and progestins.
Insulins: Metreleptin may enhance the hypoglycemic effect of Insulins.
Sulfonylureas: Metreleptin may enhance the hypoglycemic effect of Sulfonylureas.
Theophylline: Metreleptin may decrease the serum concentration of Theophylline.
Warfarin: Metreleptin may decrease the serum concentration of Warfarin.
Hepatic Dose :
No dose adjustments are recommended.